Johnson & Johnson (NYSE:JNJ) Shares Sold by Stolper Co

Stolper Co cut its stake in Johnson & Johnson (NYSE:JNJ) by 0.2% in the first quarter, Holdings Channel reports. The fund owned 34,215 shares of the company’s stock after selling 80 shares during the period. Johnson & Johnson accounts for about 1.9% of Stolper Co’s portfolio, making the stock its 22nd largest holding. Stolper Co’s holdings in Johnson & Johnson were worth $5,674,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Beese Fulmer Investment Management Inc. increased its holdings in shares of Johnson & Johnson by 2.2% during the 1st quarter. Beese Fulmer Investment Management Inc. now owns 128,693 shares of the company’s stock worth $21,343,000 after buying an additional 2,740 shares during the last quarter. Investors Research Corp lifted its stake in shares of Johnson & Johnson by 8.1% in the 1st quarter. Investors Research Corp now owns 2,426 shares of the company’s stock valued at $402,000 after purchasing an additional 181 shares during the last quarter. Fulcrum Capital LLC grew its holdings in shares of Johnson & Johnson by 26.0% during the 1st quarter. Fulcrum Capital LLC now owns 4,981 shares of the company’s stock worth $826,000 after purchasing an additional 1,029 shares during the period. Atlas Brown Inc. increased its position in shares of Johnson & Johnson by 0.7% during the 1st quarter. Atlas Brown Inc. now owns 34,716 shares of the company’s stock worth $5,757,000 after purchasing an additional 225 shares during the last quarter. Finally, Winthrop Advisory Group LLC raised its holdings in Johnson & Johnson by 4.3% in the 1st quarter. Winthrop Advisory Group LLC now owns 9,407 shares of the company’s stock valued at $1,560,000 after buying an additional 384 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on JNJ. Wall Street Zen downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 22nd. Barclays decreased their price target on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 17th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Raymond James cut their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research note on Monday, April 14th. Finally, The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Stock Up 0.9%

Johnson & Johnson stock opened at $154.99 on Friday. The stock’s fifty day moving average is $154.31 and its two-hundred day moving average is $153.65. The stock has a market cap of $372.92 billion, a PE ratio of 23.31, a P/E/G ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.36%. Johnson & Johnson’s dividend payout ratio (DPR) is 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.